血浆血管内皮生长因子家族蛋白与前置胎盘的因果关联：孟德尔随机化研究-现代医学

血浆血管内皮生长因子家族蛋白与前置胎盘的因果关联：孟德尔随机化研究

单位：石家庄市第四医院检验科, 河北石家庄 050035

分类号：R714.2； R714.5

出版年·卷·期（页码）：2024·52·第七期（1024-1030）

摘要：

目的：利用两样本孟德尔随机化(MR)方法探究血浆血管内皮生长因子(VEGF)家族蛋白与前置胎盘之间的因果关联。方法：在UK Biobank和IEU数据库中选择血浆VEGF家族蛋白的全基因组关联研究(GWAS)数据，在芬兰基因组数据库FinnGen中选择前置胎盘的GWAS数据，根据设定的阈值筛选工具变量，采用逆方差加权法(IVW)、MR-Egger、加权中位数法和加权模型进行两样本MR分析，其中IVW作为主要分析方法。进行Cochran's Q检验验证MR结果的异质性，MR-Egger回归和MR-PRESSO法评估结果的水平多效性，留一法验证结果的敏感性。结果：血浆VEGFA与前置胎盘的高风险具有因果关联(P＜0.05，OR＞1)，血浆VEGFB、VEGFC、VEGFD和胎盘生长因子(PLGF)均与前置胎盘的风险无因果关联。Cochran's Q检验显示MR分析结果无异质性。MR-Egger回归和MR-PRESSO法显示不存在水平多效性。留一法结果显示没有任何单一的工具变量会对MR分析结果产生强烈影响。结论：血浆VEGFA与前置胎盘之间存在因果关联，检测血浆VEGFA对于预测前置胎盘可能具有临床意义。

Objective: To explore the causal association between plasma vascular endothelial growth factor(VEGF) family proteins and placenta praevia using a two-sample Mendelian randomization(MR) analysis. Methods: Genome-wide association study(GWAS) data of plasma VEGF family proteins were obtained from the UK Biobank and IEU database, and the GWAS data of placenta praevia were obtained from the FinnGen database. The instrument variables were screened out according to the set threshold. Two-sample MR analysis was performed using inverse-variance weighted(IVW), MR-Egger, weighted median, and weighted mode method, with IVW as the primary analysis method. Cochran's Q test was employed for testing heterogeneity of the results. MR-Egger regression and MR-PRESSO method were conducted to assess horizontal pleiotropy of the results. The leave-one-out method was employed to verify the sensitivity of the results. Results: Plasma VEGFA was causally associated with an increased risk of placenta praevia(P<0.05, OR>1), while plasma VEGFB, VEGFC, VEGFD and placental growth factor(PLGF) were not causally associated with the risk of placenta praevia. Cochran's Q test showed that there was no heterogeneity in the results of the MR analysis. MR-Egger regression and MR-PRESSO method showed that there was no horizontal pleiotropy in the results of the MR analysis. Leave-one-out method demonstrated that no single instrumental variable strongly influenced the MR results. Conclusion: The present study indicates a causal association between plasma VEGFA and placenta praevia, suggesting that detecting plasma VEGFA may have clinical significance for predicting placenta praevia.

参考文献：

[1] MATSUO K,SANGARA R N,MATSUZAKI S,et al.Placenta previa percreta with surrounding organ involvement:a proposal for management[J].Int J Gynecol Cancer,2023,33(10):1633-1644.
[2] BACHMANN C,ABELE H,HOOPMANN M.Placenta previa et percreta: a potentially life-threatening condition[J].Diagnostics(Basel),2023,13(3):539.
[3] 胡燕,钱惠勤,季璇,等.睡眠障碍与卒中风险的因果关系：孟德尔随机化研究[J].东南大学学报(医学版),2021,40(3):330-334.
[4] JENABI E,SALIMI Z,BASHIRIAN S,et al.The risk factors associated with placenta previa: an umbrella review[J].Placenta,2022,117:21-27.
[5] ÖZGÖKÇE Ç,ÖCAL A,ERMIŞ I S.Expression of NF-κB and VEGF in normal placenta and placenta previa patients[J].Adv Clin Exp Med,2023,32(3):297-306.
[6] PÉREZ-GUTIÉRREZ L,FERRARA N.Biology and therapeutic targeting of vascular endothelial growth factor A[J].Nat Rev Mol Cell Biol,2023,24(11):816-834.
[7] FARAJI A,AKBARZADEH-JAHROMI M,BAHRAMI S,et al.Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum[J].J Obstet Gynaecol,2022,42(5):900-905.
[8] BIBEROGLU E,KIRBAS A,DAGLAR K,et al.Serum angiogenic profile in abnormal placentation[J].J Matern Fetal Neonatal Med,2016,29(19):3193-3197.
[9] WANG N,SHI D,LI N,et al.Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa[J].Ann Med,2021,53(1):2041-2049.
[10] ZHANG F,GU M,CHEN P,et al.Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio[J].Placenta,2022,124:48-54.
[11] SKRIVANKOVA V W,RICHMOND R C,WOOLF B A R,et al.Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement[J].JAMA,2021,326(16):1614-1621.
[12] DAVEY SMITH G,HEMANI G.Mendelian randomization: genetic anchors for causal inference in epidemiological studies[J].Hum Mol Genet,2014,23(R1):R89-98.
[13] SUN B B,CHIOU J,TRAYLOR M,et al.Plasma proteomic associations with genetics and health in the UK Biobank[J].Nature,2023,622(7982):329-338.
[14] FOLKERSEN L,FAUMAN E,SABATER-LLEAL M,et al.Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease[J].PLoS Genet,2017,13(4):e1006706.
[15] VERBANCK M,CHEN C Y,NEALE B,et al.Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J].Nat Genet,2018,50(5):693-698.
[16] REIJNDERS I F,MULDERS A,KOSTER M P H,et al.First-trimester utero-placental(vascular) development and embryonic and fetal growth: the Rotterdam periconception cohort[J].Placenta,2021,108:81-90.
[17] LUENGAS-MARTINEZ A,PAUS R,YOUNG H S.Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis[J].Br J Dermatol,2022,186(5):782-791.
[18] BYZOVA T V.“Fishing” out the real VEGFs[J].Blood,2016,128(19):2283-2284.
[19] BHATTACHARJEE J,MOHAMMAD S,GOUDREAU A D,et al.Physical activity differentially regulates VEGF, PLGF, and their receptors in the human placenta[J].Physiol Rep,2021,9(2):e14710.
[20] MABETA P,STEENKAMP V.The VEGF/VEGFR axis revisited: implications for cancer therapy[J].Int J Mol Sci,2022,23(24):15585.
[21] HU C,WU Z,HUANG Z,et al.Nox2 impairs VEGF-A-induced angiogenesis in placenta via mitochondrial ROS-STAT3 pathway[J].Redox Biol,2021,45:102051.
[22] XIE H,QIAO P,LU Y,et al.Increased expression of high mobility group box protein 1 and vascular endothelial growth factor in placenta previa[J].Mol Med Rep,2017,16(6):9051-9059.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录